Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.55 |
| ▸ | ECE1 | P42892 | 1/20 | 0.55 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 9/20 | 0.49 |
| ▸ | MMP1 | P03956 | 4/20 | 0.49 |
| ▸ | MMP3 | P08254 | 4/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443866 | 1.00 | MME (0.55) | MMEECE1RENMMP2MMP1 | |
| SCHEMBL7378502 | 0.93 | HDAC3 (0.53) | MME | |
| SCHEMBL7301616 | 0.91 | REN (0.48) | MMEECE1RENMMP2MMP1 | |
| SCHEMBL6443855 | 0.84 | MME (0.67) | MMEECE1RENMMP2 | |
| SCHEMBL6443861 | 0.84 | MME (0.67) | MMEECE1RENMMP2 | |
| SCHEMBL6447064 | 0.82 | MME (0.54) | MMEECE1MMP2MMP1MMP3 | |
| SCHEMBL6447062 | 0.82 | MME (0.54) | MMEECE1MMP2MMP1MMP3 | |
| SCHEMBL6447060 | 0.82 | MME (0.54) | MMEECE1MMP2MMP1MMP3 | |
| SCHEMBL9069240 | 0.81 | MME (0.70) | MME | |
| SCHEMBL7272942 | 0.81 | MME (0.52) | MMEECE1RENMMP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | MME 11/4885ECE1 172/4885REN 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.